Encoded Therapeutics has met with the U.S. Food and Drug Administration (FDA) and the two have aligned on the design of a pivotal clinical trial to support a potential approval filing for ETX101, a one-time gene therapy designed to address the underlying cause of Dravet syndrome. ETX101 is…